Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accumulated Expenses (2021 - 2025)

Historic Accumulated Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $30.9 million.

  • Kiniksa Pharmaceuticals International's Accumulated Expenses fell 2337.35% to $30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.9 million, marking a year-over-year decrease of 2337.35%. This contributed to the annual value of $32.4 million for FY2024, which is 1668.71% up from last year.
  • Kiniksa Pharmaceuticals International's Accumulated Expenses amounted to $30.9 million in Q3 2025, which was down 2337.35% from $36.0 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Accumulated Expenses' 5-year high stood at $44.7 million during Q1 2024, with a 5-year trough of $20.9 million in Q1 2023.
  • Moreover, its 5-year median value for Accumulated Expenses was $32.4 million (2024), whereas its average is $33.0 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 11411.54% in 2024, then plummeted by 5052.1% in 2025.
  • Kiniksa Pharmaceuticals International's Accumulated Expenses (Quarter) stood at $38.0 million in 2021, then dropped by 20.82% to $30.1 million in 2022, then dropped by 7.92% to $27.7 million in 2023, then rose by 16.69% to $32.4 million in 2024, then decreased by 4.37% to $30.9 million in 2025.
  • Its Accumulated Expenses was $30.9 million in Q3 2025, compared to $36.0 million in Q2 2025 and $22.1 million in Q1 2025.